# Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

> **NCT04685616** · PHASE3 · RECRUITING · sponsor: **University College, London** · enrollment: 1042 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **RADIATION:** Involved site radiotherapy
- **DRUG:** Doxorubicin
- **DRUG:** Bleomycin
- **DRUG:** Brentuximab vedotin
- **DRUG:** Vinblastine
- **DRUG:** Dacarbazine
- **DRUG:** Haematopoietic growth factor

## Key facts

- **NCT ID:** NCT04685616
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-14
- **Primary completion:** 2030-09
- **Final completion:** 2032-09
- **Target enrollment:** 1042 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04685616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04685616, "Brentuximab Vedotin in Early Stage Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04685616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*